Research Desk Line-up: Amphastar Pharma Post Earnings Coverage
LONDON, UK / ACCESSWIRE / September 8, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Dr. Reddy's Laboratories Ltd (NYSE: RDY), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=RDY. The Company announced on September 06, 2017, that it had launched Metaxalone Tablets, USP 800 mg, a therapeutic equivalent generic version of Skelaxin (metaxalone) tablets, approved by the US FDA. The Skelaxin brand and generic had US sales of about $139 million MAT for the most recent full-year ended July 2017. For immediate access to our complimentary reports, including today's coverage, register for free now at:http://protraderdaily.com/register/
Discover more of our free reports coverage from other companies within the Drug Manufacturers - Other industry. Pro-TD has currently selected Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) for due-diligence and potential coverage as the Company reported on August 09, 2017, its financial results for Q2 which ended on June 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Amphastar Pharma when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on RDY; also brushing on AMPH. Go directly to your stock of interest and access today's free coverage at:
http://protraderdaily.com/optin/?symbol=RDY
http://protraderdaily.com/optin/?symbol=AMPH
Metaxalone
The USP 800 mg Metaxalone tablets, launched in the American market are a generic version of King Pharmaceuticals Research and Development Inc.'s Skelaxin tablets. Metaxalone is a muscle relaxant which works by blocking nerve impulses, or pain sensations in the brain. It is used together with rest and physical therapy to treat skeletal muscle conditions such as pain or injury. It is also used to relax certain muscles of the body and release the discomfort caused by acute, painful muscle or bone conditions. Metaxalone acts on the CNS to relax muscles, and treat stiffness in muscles caused by strains, sprains, or other injury.
The Generic Wellbutrin XL
Additionally, Dr. Reddy's Labs announced on September 06, 2017, the launch of Bupropion Hydrochloride Extended-Release Tablets, USP, 150 mg and 300 mg, a therapeutic equivalent generic version of Wellbutrin XL Tablets, approved by the US FDA. The Wellbutrin brand and generic had US sales of about $754 million MAT for the full-year ended July 2017, where the brand is a trademark of GlaxoSmithKline LLC.
Wellbutrin is an antidepressant of the aminoketone class and is chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion and is related to phenylethylamines. It is used to treat major depressive disorder and seasonal affective disorder. Wellbutrin works by inhibiting the reuptake of dopamine, serotonin, and norepinephrine, an action that results in more dopamine, serotonin, and norepinephrine to transmit a message to other nerves.
Company Growth Prospects
Prior to the announcement, on August 28, 2017, the Company announced that it had launched Cefixime for Oral Suspension, USP 100 mg/5ml and 200 mg/5ml, a therapeutic equivalent generic version of Suprax for Oral Suspension, approved by the US FDA. The Suprax brand and generic had US sales of about $50.5 million for the 12-month period ended in June 2017.
The Company also announced on August 22, 2017, that it had out-licensed the future development, manufacturing, and commercialization rights of DFD-06, a topical high potency steroid, to Encore Dermatology, Inc., where the drug is intended to be used for the treatment of moderate to severe plaque psoriasis. Under terms of the agreement, Encore Dermatology would be responsible for the commercialization of DFD-06 in the United States. Promius Pharma was announced to be eligible to receive certain pre- and post- commercialization milestone payments up to $32.5 million, followed by fixed royalty payment on net sales.
Last Close Stock Review
At the close of trading session on Thursday, September 07, 2017, Dr. Reddy's Labs' stock price climbed 1.00% to end the day at $34.46. A total volume of 240.03 thousand shares were exchanged during the session. In the last month, shares of the Company have advanced 4.84%. The Company's shares are trading at a PE ratio of 32.21 and have a dividend yield of 0.90%. At Thursday's closing price, the stock's net capitalization stands at $5.66 billion.
Pro-Trader Daily:
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily